Curis, Inc. CRIS
Curis, Inc. (Nasdaq: CRIS) is an oncology drug developer. Its lead program, emavusertib (CA-4948), is in Phase 2 for R/R primary CNS lymphoma; CLL. Its next catalyst on record is emavusertib (CA-4948): First CLL Phase 2 patient expected late Q4 2025 or early Q1 2026, with data expected at ASH in December 2026. (December 2026).
Upcoming catalysts
- December 2026emavusertib (CA-4948) — First CLL Phase 2 patient expected late Q4 2025 or early Q1 2026, with data expected at ASH in December 2026.
we expect to enroll our first patient in late Q4 or early Q1, with data expected at the ASH annual meeting in December 2026.
Next further out: emavusertib — Regulatory path for single-arm PCNSL study (accelerated/conditional approval) (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| emavusertib | PCNSL (TakeAim Lymphoma Phase 1/2 with ibrutinib) | small molecule | Phase 2 |
| emavusertib | CLL (TakeAim CLL Phase 2) | small molecule | Phase 2 |
Recent results and decisions
- Mar 19, 2026positive SNO poster (24 pts): 100% ORR (5/5) in BTKi-naive and 37% ORR (7/19) in BTKi-experienced patients.
5 of 5 BTKi-naïve patients achieved objective response (100% ORR)
Filing - Mar 19, 2026started Curis initiated open-label Phase 2 study of emavusertib with zanubrutinib in CLL.
Curis initiated an open label Phase 2 clinical study of emavusertib in combination with zanubrutinib, a BTKi, in patients with Chronic Lymphocytic Leukemia (CLL).
Filing - Nov 3, 2025positive Abstract data (July 2 cutoff, 10 pts): MRD conversion to undetectable in 4 of 8 patients (50%); two DLTs in 14-day cohort, both resolved.
MRD conversion (positive to undetectable) was observed in 4 of 8 patients (50%)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.